Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Roivant Sciences Ltd
(NQ:
ROIV
)
12.23
+0.21 (+1.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roivant Sciences Ltd
< Previous
1
2
3
4
5
6
7
Next >
Analyst Expectations for Roivant Sciences's Future
March 16, 2023
Via
Benzinga
Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years
March 15, 2023
Via
Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
March 15, 2023
From
Roivant Sciences
Via
GlobeNewswire
Expert Ratings for Roivant Sciences
February 13, 2023
Via
Benzinga
Roivant Sciences's Earnings Outlook
February 10, 2023
Via
Benzinga
Where Roivant Sciences Stands With Analysts
January 19, 2023
Via
Benzinga
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
March 14, 2023
From
Roivant Sciences
Via
GlobeNewswire
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
March 14, 2023
PVTX-321 and PVTX-405 Achieve Development Candidate Nomination
From
Roivant Sciences
Via
GlobeNewswire
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
March 07, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Announces Change to its Board of Directors
February 21, 2023
From
Roivant Sciences
Via
GlobeNewswire
Immunovant Could Potentially Be An M&A Target, Writes Analyst
February 15, 2023
Via
Benzinga
Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data
February 14, 2023
Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.
Via
Benzinga
Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
February 13, 2023
From
Roivant Sciences
Via
GlobeNewswire
Earnings Scheduled For February 13, 2023
February 13, 2023
Companies Reporting Before The Bell • EuroDry (NASDAQ:EDRY) is expected to report quarterly earnings at $2.68 per share on revenue of $21.20 million.
Via
Benzinga
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
February 02, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Announces Proposed Public Offering of Common Shares
February 01, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
January 30, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Touts Encouraging Early Data From Ulcerative Colitis Candidate
January 04, 2023
Via
Benzinga
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker
January 04, 2023
From
Roivant Sciences
Via
GlobeNewswire
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
December 19, 2022
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5. Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on...
Via
Benzinga
Why Roivant Sciences' Shares Are Up Thursday
December 01, 2022
The company is collaborating with Pfizer to create a portfolio company to develop an encouraging drug to treat ulcerative colitis.
Via
The Motley Fool
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
December 01, 2022
From
Roivant Sciences
Via
GlobeNewswire
Pinterest To $23? Plus This Analyst Slashes PT On Neoleukin Therapeutics By More Than 90%
November 15, 2022
Rosenblatt raised the price target on Pinterest, Inc. (NYSE: PINS) from $21 to $23. Rosenblatt analyst Barton Crockett maintained a Neutral rating on the stock. Pinterest shares rose 2% to $24.91 in...
Via
Benzinga
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
November 15, 2022
Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.
Via
Benzinga
Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
November 14, 2022
From
Roivant Sciences
Via
GlobeNewswire
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
November 10, 2022
From
Roivant Sciences
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 08, 2022
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The company's market cap stands at $2.8 million.
Via
Benzinga
Earnings Scheduled For November 14, 2022
November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Via
Benzinga
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
November 08, 2022
From
Roivant Sciences
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.